Neon Therapeutics Inc (NASDAQ:NTGN) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 621,800 shares, an increase of 8.3% from the January 15th total of 573,900 shares. Based on an average trading volume of 344,300 shares, the short-interest ratio is presently 1.8 days. Currently, 4.5% of the shares of the stock are sold short.

Shares of NASDAQ:NTGN traded up $0.03 during midday trading on Friday, reaching $1.45. The company had a trading volume of 165,500 shares, compared to its average volume of 503,568. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.59 and a current ratio of 4.59. Neon Therapeutics has a 1-year low of $0.88 and a 1-year high of $7.51. The firm has a market cap of $40.24 million, a price-to-earnings ratio of -0.47 and a beta of 1.26. The company has a fifty day simple moving average of $1.40 and a two-hundred day simple moving average of $1.87.

Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.04). Analysts expect that Neon Therapeutics will post -2.42 EPS for the current year.

A number of research analysts recently issued reports on the company. Bank of America lowered Neon Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, November 13th. Robert W. Baird lowered Neon Therapeutics from an “outperform” rating to a “neutral” rating in a report on Thursday, January 16th. HC Wainwright reaffirmed a “neutral” rating on shares of Neon Therapeutics in a report on Tuesday, January 21st. Mizuho lowered their target price on Neon Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Finally, Zacks Investment Research lowered Neon Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Neon Therapeutics has a consensus rating of “Hold” and an average price target of $8.74.

In related news, insider Richard Gaynor sold 20,000 shares of Neon Therapeutics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $1.37, for a total transaction of $27,400.00. Following the transaction, the insider now directly owns 201,822 shares of the company’s stock, valued at $276,496.14. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 38.93% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in the stock. Morgan Stanley boosted its position in shares of Neon Therapeutics by 10.8% in the 2nd quarter. Morgan Stanley now owns 40,522 shares of the company’s stock valued at $192,000 after purchasing an additional 3,939 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of Neon Therapeutics in the 1st quarter valued at $49,000. UBS Group AG boosted its position in shares of Neon Therapeutics by 70.6% in the 4th quarter. UBS Group AG now owns 25,293 shares of the company’s stock valued at $30,000 after purchasing an additional 10,469 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Neon Therapeutics by 27.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 57,814 shares of the company’s stock valued at $68,000 after purchasing an additional 12,396 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Neon Therapeutics by 8.5% in the 2nd quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock valued at $789,000 after purchasing an additional 12,971 shares during the period. Institutional investors and hedge funds own 58.33% of the company’s stock.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Story: Golden Cross

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.